Guardant Health, INC Form 4 insider transactions

Guardant Health's Chief Financial Officer, Michael Brian Bell, was granted 26,582 restricted stock units with a three-year vesting schedule.

Guardant Health's Chief Information Officer, Kumud Kalia, exercised stock options and subsequently sold a portion of the acquired shares.

Guardant Health Director Steve Krognes converted 154 restricted stock units into common stock on February 28, 2026.

Guardant Health Director Roberto Mignone converted 264 Restricted Stock Units into common stock, increasing his direct holdings.

Guardant Health Director Steve Krognes reported the vesting of 154 restricted stock units, converting them into common stock.

Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 8,571 shares of common stock for approximately $977,440 through a pre-arranged 10b5-1 plan.

Guardant Health Director Roberto Mignone reported the acquisition of 264 shares of common stock and 264 restricted stock units.

Guardant Health Director Manuel Hidalgo Medina converted 232 restricted stock units into common stock on January 17, 2026.

Guardant Health Director Musa Tariq acquired 250 shares of common stock and 250 restricted stock units on January 15, 2026, as part of a vesting schedule.

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 10,031 shares of common stock under a pre-arranged trading plan.

Guardant Health's Chief Legal Officer, John G. Saia, increased his beneficial ownership of common stock through the vesting of restricted stock units and performance-based restricted stock units on January 1, 2026.

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and related tax-driven share disposals.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported multiple equity transactions related to RSU and PBRSU vesting on January 1, 2026, including shares withheld for tax obligations.

Guardant Health's Chief Medical Officer, Craig Eagle, reported multiple equity transactions including RSU vestings and shares withheld for tax obligations.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of various restricted stock units and performance-based restricted stock units on January 1, 2026, alongside shares withheld for tax obligations.

Guardant Health's CFO, Michael Brian Bell, reported multiple stock unit vestings and a tax-related share disposition on January 1, 2026.

Guardant Health Co-Chief Executive Officer AmirAli Talasaz reported the conversion of restricted stock units into common stock and subsequent tax-related dispositions.

Guardant Health's Co-CEO, Helmy Eltoukhy, increased his direct beneficial ownership of common stock by 13,209 shares through restricted stock unit vestings and associated tax withholdings.

Guardant Health Director Steve E. Krognes reported the vesting and acquisition of 154 shares of common stock from restricted stock units.

Guardant Health Director Roberto Mignone converted 264 restricted stock units into common stock, increasing his direct beneficial ownership.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock on December 17, 2025, through the vesting of restricted stock units.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $101.46 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Musa Tariq acquired 250 shares of common stock through the exercise of restricted stock units on December 15, 2025.

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and a subsequent tax-related sale of company stock.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported the sale of 90,565 shares of common stock for approximately $9.4 million.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.